Compare · AVTR vs PACB
AVTR vs PACB
Side-by-side comparison of Avantor Inc. (AVTR) and Pacific Biosciences of California Inc. (PACB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and PACB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $9.75B, about 20.6x PACB ($472.5M).
- PACB has been more active in the news (7 items in the past 4 weeks vs 3 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 24 for PACB).
- Company
- Avantor Inc.
- Pacific Biosciences of California Inc.
- Price
- $14.41+1.02%
- $1.52+18.75%
- Market cap
- $9.75B
- $472.5M
- 1M return
- +22.53%
- -
- 1Y return
- +8.47%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2010
- News (4w)
- 3
- 7
- Recent ratings
- 25
- 24
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest AVTR
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
- SVP & Chief Accounting Officer Eck Steven W covered exercise/tax liability with 1,385 shares, decreasing direct ownership by 1% to 129,593 units (SEC Form 4) to satisfy withholding tax
- Avantor upgraded by Jefferies with a new price target
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports Second Quarter 2026 Results
- EVP, Chief Legal & Compliance Sokenu Claudius covered exercise/tax liability with 1,201 shares, decreasing direct ownership by 0.48% to 251,228 units (SEC Form 4) to cover withholding tax
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
Latest PACB
- Officer Van Oene Mark sold $30,409 worth of shares (26,911 units at $1.13), decreasing direct ownership by 0.98% to 2,705,853 units (SEC Form 4) to satisfy withholding obligation
- Officer Van Oene Mark was granted 489,130 shares, increasing direct ownership by 22% to 2,732,764 units (SEC Form 4)
- SEC Form 10-Q filed by Pacific Biosciences of California Inc.
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- PacBio Appoints Mark Van Oene as President and Chief Executive Officer
- PacBio Announces Second Quarter 2026 Financial Results
- PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
- PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
- PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update